Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Hyphema · children at or before five years of age with primary congenital glaucoma
Microcatheter‐assisted trabeculotomy probably leads to higher adverse outcomes— hyphema Up to 1 year after surgery compared with conventional trabeculotomy (moderate certainty).
1 finding from 1 review
Change in weight (kg) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Change in height · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
CFA: change from baseline (%) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Adverse events · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · children aged 7 years or over and adults with cystic fibrosis
Summary of findings: liprotamase showed no clear difference in pulmonary exacerbations: number of exacerbations compared with porcine PERT (low certainty).
1 finding from 1 review
All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
All‐cause mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes mortality compared with rituximab (very low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.44 [0.11, 1.81]
Studies not reported
Very low
Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.22 [0.03, 1.6]
Studies not reported
Very low